Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombolytic Therapy | 4 | 2016 | 257 | 1.370 |
Why?
|
| Fibrinolytic Agents | 4 | 2016 | 324 | 1.320 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2016 | 105 | 0.940 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2016 | 342 | 0.880 |
Why?
|
| Electrocardiography | 5 | 2016 | 1145 | 0.560 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 1374 | 0.550 |
Why?
|
| Thoracic Injuries | 1 | 2013 | 58 | 0.460 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2015 | 314 | 0.460 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 292 | 0.450 |
Why?
|
| Pericardial Effusion | 1 | 2013 | 118 | 0.440 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2013 | 176 | 0.420 |
Why?
|
| Tachycardia, Ventricular | 1 | 2013 | 239 | 0.380 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2016 | 136 | 0.370 |
Why?
|
| Apolipoprotein A-I | 1 | 2009 | 84 | 0.350 |
Why?
|
| Apolipoproteins B | 1 | 2009 | 106 | 0.350 |
Why?
|
| Cross-Cultural Comparison | 1 | 2009 | 87 | 0.340 |
Why?
|
| Myocardium | 1 | 2015 | 1313 | 0.330 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 429 | 0.330 |
Why?
|
| Heptanoic Acids | 1 | 2009 | 96 | 0.330 |
Why?
|
| Cholesterol, LDL | 2 | 2009 | 565 | 0.330 |
Why?
|
| Lipids | 3 | 2010 | 644 | 0.300 |
Why?
|
| Epispadias | 1 | 2006 | 3 | 0.290 |
Why?
|
| Bladder Exstrophy | 1 | 2006 | 11 | 0.290 |
Why?
|
| Subphrenic Abscess | 1 | 2006 | 3 | 0.290 |
Why?
|
| IgA Deficiency | 1 | 2006 | 6 | 0.290 |
Why?
|
| Siblings | 1 | 2006 | 285 | 0.260 |
Why?
|
| Pyrroles | 1 | 2009 | 576 | 0.250 |
Why?
|
| Iran | 4 | 2009 | 68 | 0.220 |
Why?
|
| Cardiovascular Diseases | 3 | 2010 | 2195 | 0.210 |
Why?
|
| Time Factors | 5 | 2016 | 12926 | 0.190 |
Why?
|
| Obesity | 2 | 2009 | 2884 | 0.180 |
Why?
|
| Abnormalities, Multiple | 1 | 2006 | 998 | 0.180 |
Why?
|
| Tuberculosis | 1 | 2006 | 548 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 1362 | 0.160 |
Why?
|
| Sex Factors | 4 | 2009 | 2139 | 0.150 |
Why?
|
| Dermatologic Agents | 2 | 2007 | 53 | 0.140 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 14889 | 0.140 |
Why?
|
| Texas | 3 | 2016 | 6311 | 0.140 |
Why?
|
| Tacrolimus | 2 | 2007 | 335 | 0.130 |
Why?
|
| Male | 15 | 2016 | 123000 | 0.120 |
Why?
|
| Accidents, Traffic | 1 | 2013 | 116 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2015 | 6869 | 0.110 |
Why?
|
| Echocardiography, Doppler | 1 | 2013 | 180 | 0.110 |
Why?
|
| Survival Rate | 3 | 2016 | 12221 | 0.110 |
Why?
|
| Cross-Sectional Studies | 4 | 2009 | 4314 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2015 | 32848 | 0.100 |
Why?
|
| Amyloidosis | 1 | 2014 | 176 | 0.100 |
Why?
|
| Emergencies | 1 | 2013 | 202 | 0.100 |
Why?
|
| Sex Distribution | 2 | 2009 | 495 | 0.100 |
Why?
|
| Age Distribution | 2 | 2009 | 698 | 0.100 |
Why?
|
| Humans | 17 | 2016 | 261506 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 4938 | 0.090 |
Why?
|
| Triglycerides | 2 | 2009 | 603 | 0.090 |
Why?
|
| Sweden | 1 | 2009 | 70 | 0.090 |
Why?
|
| Female | 11 | 2016 | 141928 | 0.080 |
Why?
|
| Juglans | 1 | 2008 | 1 | 0.080 |
Why?
|
| Postoperative Care | 1 | 2013 | 739 | 0.080 |
Why?
|
| Middle Aged | 8 | 2016 | 86204 | 0.080 |
Why?
|
| Anthropometry | 1 | 2009 | 269 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2015 | 2218 | 0.080 |
Why?
|
| Educational Status | 1 | 2009 | 397 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2016 | 12873 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2009 | 341 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 610 | 0.080 |
Why?
|
| Lichen Planus, Oral | 1 | 2007 | 9 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2008 | 110 | 0.080 |
Why?
|
| Triamcinolone Acetonide | 1 | 2007 | 38 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 543 | 0.070 |
Why?
|
| Liver Cirrhosis, Experimental | 1 | 2006 | 18 | 0.070 |
Why?
|
| Opioid Peptides | 1 | 2006 | 9 | 0.070 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2006 | 8 | 0.070 |
Why?
|
| Adult | 8 | 2015 | 77950 | 0.070 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2008 | 224 | 0.070 |
Why?
|
| Facial Dermatoses | 1 | 2006 | 26 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2008 | 215 | 0.070 |
Why?
|
| Consanguinity | 1 | 2006 | 114 | 0.070 |
Why?
|
| United States | 3 | 2013 | 15433 | 0.070 |
Why?
|
| Long QT Syndrome | 1 | 2006 | 92 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2006 | 237 | 0.070 |
Why?
|
| Gastroesophageal Reflux | 1 | 2008 | 334 | 0.070 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2008 | 208 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 1225 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2006 | 388 | 0.060 |
Why?
|
| Aged | 5 | 2015 | 70117 | 0.060 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2006 | 144 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 586 | 0.060 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 538 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2008 | 1244 | 0.060 |
Why?
|
| Risk Factors | 4 | 2015 | 17523 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2007 | 629 | 0.060 |
Why?
|
| Antitubercular Agents | 1 | 2006 | 318 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2015 | 37905 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 2403 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2006 | 236 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2006 | 418 | 0.060 |
Why?
|
| Age Factors | 2 | 2009 | 5377 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2006 | 644 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2010 | 945 | 0.050 |
Why?
|
| Pedigree | 1 | 2006 | 1890 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 960 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2009 | 2203 | 0.050 |
Why?
|
| Biomarkers | 1 | 2009 | 5047 | 0.040 |
Why?
|
| Adolescent | 3 | 2013 | 31252 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2007 | 409 | 0.030 |
Why?
|
| Prognosis | 1 | 2013 | 21713 | 0.030 |
Why?
|
| Young Adult | 2 | 2009 | 21445 | 0.030 |
Why?
|
| Amyloid | 1 | 2014 | 97 | 0.030 |
Why?
|
| Child | 3 | 2009 | 29154 | 0.030 |
Why?
|
| Alloxan | 1 | 2008 | 4 | 0.020 |
Why?
|
| Glyburide | 1 | 2008 | 28 | 0.020 |
Why?
|
| Rats | 2 | 2008 | 6086 | 0.020 |
Why?
|
| Plant Leaves | 1 | 2008 | 61 | 0.020 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2010 | 197 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 2008 | 229 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1099 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2013 | 1274 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2007 | 257 | 0.020 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2006 | 61 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2010 | 235 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 139 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 1053 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2006 | 141 | 0.020 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2006 | 73 | 0.020 |
Why?
|
| Calcineurin Inhibitors | 1 | 2006 | 68 | 0.020 |
Why?
|
| Cholesterol | 1 | 2009 | 658 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2006 | 333 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2006 | 314 | 0.020 |
Why?
|
| Epinephrine | 1 | 2006 | 255 | 0.020 |
Why?
|
| Random Allocation | 1 | 2006 | 703 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2007 | 953 | 0.010 |
Why?
|
| Heart Rate | 1 | 2006 | 737 | 0.010 |
Why?
|
| Insulin | 1 | 2008 | 1454 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2006 | 2063 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 849 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 2352 | 0.010 |
Why?
|
| Animals | 3 | 2014 | 59536 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 1467 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 3719 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 1879 | 0.010 |
Why?
|
| Pain | 1 | 2007 | 1658 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 4320 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 29902 | 0.010 |
Why?
|